NEWS RELEASES

YEAR

ALL

2019

2018

2017

2016

2015

2014

CANBRIDGE PHARMACEUTICALS ENTERS INTO RARE DISEASE GENE THERAPY RESEARCH AGREEMENT WITH UMASS MEDICAL SCHOOL JUN 09, 2020
CANBRIDGE PHARMACEUTICALS RECEIVES MARKETING APPROVAL FOR NERLYNX® (NERATINIB) IN CHINA MAY 14, 2020
CANBRIDGE PHARMACEUTICALS COMPLETES US$98 MILLION SERIES D FINANCING FEB 19, 2020
SHANGHAI FOUNDATION FOR RARE DISEASE APPOINTS CANBRIDGE CEO, JAMES XUE, DEPUTY DIRECTOR GENERAL SOLE REPRESENTATIVE FROM THE PHARMACEUTICAL INDUSTRY JAN 06, 2020
CANBRIDGE RECEIVES HONG KONG DEPARTMENT OF HEALTH MARKET APPROVAL FOR NERLYNX® NOV 05, 2019
CANBRIDGE PHARMACEUTICALS’ HUNTERASE® GRANTED PRIORITY REVIEW BY THE CHINESE NATIONAL MEDICAL PRODUCTS ADMINISTRATION SEP 09, 2019

«
1
2
3
4
5
6
7
8
»

PARTNERSHIP &
RECOGNITION

WORKING AT CANBRIDGE

EMPLOYEES’ WORD

OPENING POSITIONS

TEL: 86-10-84148018

FAX: 86-10-84148017

Product Hotline: 86-400-821-5085

ADD: Suite 301，3F，Timeloit，No.17 RongChuang Road，Chaoyang District， Beijing，China

EMAIL: info@canbridgepharma.com

Adverse Events Reporting: PV@canbridgepharma.com

Copyright ©:CANbridge Life Sciences Ltd. ICP:12036158-1 Powered By Clouddream